Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics INC (KPTI)
:KPTI
Earnings Data
Report Date
Oct 30, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-3.4Last Year’s EPS
-3.9Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in clinical trials and commercial performance, especially with a steady increase in revenue from XPOVIO and global expansion efforts. However, significant financial challenges due to a net loss, decline in total revenue, and approaching debt maturity are concerning. The company is actively working on strategic alternatives to enhance liquidity.Company Guidance
Solid Commercial Performance
The company delivered solid commercial results in Q2 2025, with XPOVIO net product revenue of $29.7 million, up 6% from the second quarter of 2024. Demand for XPOVIO remained consistent, driven by the community setting.
Progress in Clinical Trials
Enrollment in the Phase III SENTRY trial for myelofibrosis is expected to close soon. Preliminary safety data suggest that the combination of selinexor and ruxolitinib may have a favorable safety profile.
Global Expansion
Selinexor and NEXPOVIO are now approved in various indications in 50 countries, leading to a 28% increase in royalty revenue to $1.6 million in Q2 2025 compared to Q2 2024.
Cost Reduction Initiatives
R&D expenses decreased by 15%, and SG&A expenses decreased by 8% in Q2 2025 compared to Q2 2024, reflecting the realization of cost optimization efforts.
KPTI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KPTI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 11, 2025 | $3.94 | $3.77 | -4.31% |
May 12, 2025 | $6.15 | $4.92 | -20.00% |
Feb 19, 2025 | $9.45 | $9.00 | -4.76% |
Nov 05, 2024 | $14.00 | $12.68 | -9.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Karyopharm Therapeutics INC (KPTI) report earnings?
Karyopharm Therapeutics INC (KPTI) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).
What is Karyopharm Therapeutics INC (KPTI) earnings time?
Karyopharm Therapeutics INC (KPTI) earnings time is at Oct 30, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KPTI EPS forecast?
KPTI EPS forecast for the fiscal quarter 2025 (Q3) is -3.4.